FDA Drug Safety Communications
Saturday, February 7, 2026
FDA Requests Removal of Suicidal Behavior Warning from GLP-1 RA Medications
The FDA is requesting that drug manufacturers remove the warning about suicidal ideation and behavior from the labeling of GLP-1 RA medications approved for weight reduction. This action follows a comprehensive review that found no increased risk associated with these drugs.
Priority review
Guidance
Pharmaceuticals
Source details
Activity
Browse Categories
Agriculture & Food Safety
61
Banking & Finance
163
Consumer Protection
29
Courts & Legal
206
Data Privacy & Cybersecurity
58
Defense & National Security
48
Education
20
Energy
93
Environment
81
Government & Legislation
240
Healthcare
104
Housing
15
Immigration
8
Insurance
16
Labor & Employment
104
Pharma & Drug Safety
68
Securities & Markets
69
Tax
48
Telecom & Technology
34
Trade & Sanctions
113
Transportation
53
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get FDA Drug Safety Communications alerts
We'll email you when FDA Drug Safety Communications publishes new changes.